Intersect ENT has developed the PROPEL dissolvable sinus implant to improve surgical outcomes for chronic sinusitis sufferers.

PROPEL is the first of a new category of products offering localized, controlled drug delivery directly to the sinus tissue. Inserted by a physician to maintain the surgical opening, the spring-like implant expands to prop open the ethmoid sinus and gradually delivers an advanced corticosteroid with anti-inflammatory properties directly to the sinus lining where it’s needed most as the implant dissolves.

The PROPEL system has been clinically proven to prevent obstruction of the ethmoid sinus following surgery. Obstruction can occur due to recurrent scarring and inflammation. The result is improved post-operative outcomes, reducing the need for additional surgical procedures and systemic steroids that can have serious side effects.*


Innovative yet intuitive.

  • PROPEL Delivery System is directed to the open surgical cavity.

  • The PROPEL implant’s spring-like design conforms to patient’s unique anatomy and props open the sinus.

  • Sustained, local release of mometasone furoate over 30 days.*

  • Eventually dissolves.


The PROPEL system leverages Sustained Release Technology, which allows for local, sustained drug delivery directly to the sinus mucosa. Mometasone furoate is embedded in a highly customized polymer, which controls the release of drug over time as the implant dissolves. The self-expanding nature of PROPEL ensures the implant props open the cavity and apposes the tissue to maximize targeted drug delivery.